BiotechTube

Ustekinumab 45 mg + Ustekinumab 90 mg

Pre-clinicalRecruiting
1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease, Plaque Psoriasis

Trial Timeline

Mar 17, 2025 → Dec 31, 2027

NCT ID
NCT06997055

About Ustekinumab 45 mg + Ustekinumab 90 mg

Ustekinumab 45 mg + Ustekinumab 90 mg is a pre-clinical stage product being developed by Celltrion for Crohn Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06997055. Target conditions include Crohn Disease, Plaque Psoriasis.

What happened to similar drugs?

12 of 20 similar drugs in Crohn Disease were approved

Approved (12) Terminated (4) Active (8)
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅MirikizumabEli LillyApproved
✅Adalimumab Injection + ThiopurineAbbVieApproved
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved

Hype Score Breakdown

Clinical
3
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06997055Pre-clinicalRecruiting

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
42
CT-P13 + RemicadeCelltrionPhase 3
40
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
39
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CP-461Astellas PharmaPhase 2
35
UstekinumabSun PharmaceuticalPre-clinical
33
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44